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Abstract  
The skin is the largest organ of the integumentary system and possesses a vast number of 
functions. Due to the distinct layers of the skin and the variety of cells that populate each, a 
tightly regulated network of molecular signals control development and regeneration, whether 
due to programmed cell termination or injury. MicroRNAs (miRs) are a relatively recent 
discovery; they are a class of small non-coding RNAs that possess a multitude of biological 
functions due to their ability to regulate gene expression via post-transcriptional gene silencing. 
Of interest, is that a plethora of data demonstrates that a number of miRs are highly expressed 
within the skin, and are evidently key regulators of numerous vital processes to maintain non-
aberrant functioning. Recently, miRs have been targeted as therapeutic interventions due to the 
ability of synthetic ‘antagomiRs’ to downregulate abnormal miR expression, thereby 
potentiating wound healing and attenuating fibrotic processes which can contribute to disease 
such as systemic sclerosis (SSc). This review will provide an introduction to the structure and 
function of the skin and miR biogenesis, before summarising the literature pertaining to the 
role of miRs. Finally, miR therapies will also be discussed, highlighting important future areas 
of research. 
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1. Introduction 
1.1 Skin 
The skin is the largest and one of the most varied organs of the body, and possesses a vast 
number of functions including thermoregulation, protection from external stimuli and 
pathogens, as well as water resistance. Composed of three layers, the skin acts as a protective 
barrier against environmental exposures. The top layer, the epidermis, is composed of 
proliferating basal and differentiated suprabasal keratinocytes, in addition to melanocytes, 
Langerhans and Merkel cells.  
Keratinocytes are the most abundant cell type located in the epidermis and possess a number 
of immune functions. For example, they exert a protective role via secretion of chemokines 
upon invasion of a pathogenic threat (1). Production of a broad range cytokines, with both pro- 
and anti-inflammatory functions also occurs (2). Expression of various Toll-like receptors 
(TLRs) contributes to the defence of the skin against antimicrobial pathogens (3). In addition 
to their immune functions, they also secrete keratin, a key structural protein, and finally become 
the cornified layer once the cells flatten. Melanoblasts proliferate and colonise in the epidermis 
as melanocytes. Located in the basal layer, these cells produce melanin, the pigment found in 
skin, hair and eyes that protects against UV radiation (4). Keratinocytes stimulate the 
proliferation and differentiation of melanocytes, in addition to melanogenesis. Epidermal and 
follicular homeostasis, therefore, is maintained largely by interactions between these two cell 
types (4). Langerhans cells are dendritic cells that process microbial antigens and are able to 
induce T cell differentiation and polarisation (5), in addition to activation of regulatory T cells 
(6). In contrast, Merkel cells which are located in the basal epidermis, function as 
mechanoreceptors (7). Homeostasis of the epidermis is maintained by three distinct classes of 
stem cells; bulge stem cells of located in the hair follicle, interfollicular stem cells, and 
sebaceous gland stem cells.  
The middle layer, the dermis, is populated by macrophages, lymphocytes, mast cells, and 
dendritic cells, in addition to fibroblasts which provide structural strength through production 
of  collagen and elastin fibers and other extracellular matrix proteins (8). Meissner’s and 
Pacinian corpuscles, in addition to nerve fibres and free endings, detect touch, pressure, and 
pain (9), while sweat and sebaceous glands regulate temperature. Not only do capillary 
networks in the dermis provide the epidermis with oxygen and nutrients (8), but dermal stem 
cells are able to differentiate into functional cells in the epidermis, highlighting an 
interdependence between the two layers (10). 
 Figure 1 – Structure of the epidermis and dermis. 
 
The hypodermis is primarily composed of adipocytes, and is also involved in thermoregulation 
via its insulative properties, while production of vitamin D also occurs in this subcutaneous 
layer.  
The large number of cell types and functional diversity of the skin necessitate tightly regulated 
molecular signals in order to deter aberrant growth and maintain homeostasis. MicroRNAs 
(miRs) are one group of molecules that aid in such mechanisms. 
 
1.2 MicroRNA Biogenesis and Function  
MiRs are small non-coding RNA molecules, typically ~22 nucleotides (nt) long, involved in 
RNA silencing and post-transcriptional regulation of gene expression by binding to the 3’UTR 
of its targets; target recognition occurs via a 6-8 nt site that matches the miR seed region.  Each 
miR is capable of repressing hundreds of genes, and each gene can be targeted by multiple 
miRs, making it a powerful system for the fine-tuning of gene expression. 
MiR biogenesis is similar to protein-coding genes in that upon transcription factor binding, 
RNA polymerase II transcribes the miR gene, followed by Drosha-mediated cleavage of the 
primary miR transcript resulting in a number of precursor miRs (pre-miR). A 2 nt overhang at 
the 3’ end exists as a binding site for Exportin-5 which causes translocation to the cytoplasm. 
Dicer then processes the pre-miR into a mature miR strand which is incorporated into the RNA-
induced silencing complex (RISC), which in turn, inhibits translation (see figure 2). Reduction 
in the abundance of the target mRNA may also occur via RNA cleavage or decapping and 
deadenylation. The RISC can also silence genes via formation of heterochromatin at the 
genomic level (11). A number of miRs are highly expressed in the skin, and possess a plethora 
of important functions with regard to development, homeostasis, and regeneration. The 
following sections serve to summarise the current literature within these areas. In addition, 
chemically synthesized miRs are beginning to be trialled and used as therapeutic treatments for 
a number of diseases, and will also be discussed.  
 
 
 
Figure 2 – Simplified microRNA biogenesis and incorporation into the RNA-induced 
silencing complex pathway. 
  
2. Skin Development and Homeostasis: Role of MicroRNAs 
During embryonic development, gastrulation occurs whereby the single-layered blastula 
transforms into the tri-layered gastrula. Epidermal progenitor cells of the outer layer, the 
ectoderm, cause hair follicles, sebaceous glands and the epidermis itself to grow. Mesenchymal 
cells begin to infiltrate the skin and in combination with the basal epidermal layer, begin to 
direct extracellular matrix proteins and growth factors. Once the formation of new keratinocyte 
layers (stratification) and differentiation of their properties is complete, the epidermis consists 
of distinct layers: a cornified layer (stratum corneum), a translucent layer (stratum lucidum), a 
granular layer (stratum granulosum), a spinous layer (stratum spinosum), and a basal layer 
(stratum basale). The inner layer of basal cells proliferate, while suprabasal cells terminally 
differentiate. Hair follicle morphogenesis occurs via interactions between epidermal 
keratinocytes and dermal fibroblasts. Primarily, the mesenchyme coordinates keratinocyte 
proliferation. The follicle continues to develop downwards, whereby differentiation results in 
the hair shaft and sebaceous gland. The epidermis, therefore, is composed of the interfollicular 
epidermis and a pilosebaceous unit which contains a hair follicle.  
Epidermal homeostasis is maintained by three distinct pools of stem cells located in the 
interfollicular epidermis, the bulge (a region located at the bottom of the hair follicle outer root 
sheath), and the sebaceous gland. Stem cells continuously self-renew and differentiate into 
various cell lineages, which is an essential process in order to replenish cells such as 
keratinocytes that die due to injury or programmed termination. Skin barrier renewal via 
spinous transition of basal cells in mature skin occurs concomitantly with changes to gene 
expression, for example, Keratin5/14 (K5/K14) are downregulated, and Keratin1/10 (K1/K10) 
are upregulated (12).  
The molecular signals that control the development of the skin are numerous and complex, 
with a clear role for miRs as key regulators of a variety of processes crucial to epidermal and 
follicular development and homeostasis. The importance of miRs in skin morphogenesis has 
been shown by progenitor cell Dicer knockdown in an embryonic mouse skin model in which 
hair germ cells evaginated towards the epidermis, instead of invaginating towards the dermis 
as usual (13). Interestingly, lower Dicer expression has been observed in mouse embryonic 
epidermis than the hair follicle, suggesting differential epigenetic regulation even between two 
conjoining structures (14).  
The functional consequence of Dicer knockdown is also significantly different between the 
epidermis and hair follicle; one week after birth, epidermal proliferation and apoptosis was not 
significantly altered, however, elevated apoptosis and attenuated cell proliferation inhibited 
follicular development (13, 14). In support of the postulation that differential epigenetic signals 
regulate development of the epidermis and hair follicle, the miR-19/20 and miR-200 families 
are highly expressed in the former, while conversely, the miR-199 family is exclusively 
expressed in the latter (13). 
The transcription factor p63 is essential in epidermal development, as demonstrated by the 
death of p63-deficient mice immediately following birth (15), likely as it is important in 
maintaining stem cell proliferation (16). The Notch pathway is a regulator of interfollicular 
differentiation and active primarily in suprabasal cells (17), while inhibition of this pathway 
results in a lack of skin barrier development (18). In addition, the MAPK pathway regulates 
epidermal proliferation and differentiation as evidenced by Mek1/2 deletion which results in 
underdevelopment of the skin (19). Conversely, over-activation of epidermal growth factor 
(EGF) signalling, involved in the MAPK pathway, causes augmented proliferation and 
epidermal tumour growth (20). Consistently, attenuated interfollicular proliferation occurred 
as a consequence of EGF downregulation. 
MiR-203 is expressed in both human adult and foetal skin, although expression was not 
detectable until 17 weeks (21). Evidence suggests that miR-203 is an important regulator of 
keratinocyte differentiation; Protein Kinase C (PKC) inhibition blocked miR-203 expression 
following calcium-induced differentiation, while overexpression of miR-203 significantly 
augmented differentiation (22). These data demonstrate that PKC pathway activation is 
essential for miR-203 upregulation, and thus, keratinocyte differentiation. Furthermore, miR-
203 appears to promote epidermal differentiation via decreasing proliferation. Given that p63 
regulates stem cell maintenance, miR-203-induced p63 repression is a plausible mechanism by 
which miR-203 promotes differentiation (23). SOCS3 is expressed basally in both human foetal 
and adult skin, and is also directly targeted by miR-203 (21), further supporting the role of this 
miR in skin development. 
MiR-34a, -34c, -574-3p, and -720 also appear to be regulated by p63. Inhibition of miR-34a 
and -34c restored keratinocyte cell cycle progression, while knockdown of p63 augmented both 
of these miRs concomitantly with inhibition of cell cycle regulators (24). p63 and iASPP 
(inhibitor of apoptosis stimulating protein of p53) are involved in an autoregulatory feedback 
loop; iASPP itself negatively regulates miR-574-3p and miR-720, which could, in turn, be 
negatively regulating p63. Depletion of iASPP in keratinocytes promotes differentiation 
concomitantly with an overexpression of these two miRs. Furthermore, miR-574-3p and miR-
720 expression in these cells correlate with stratification pattern (25), thereby supporting their 
role in epidermal differentiation, plausibly via downregulation of p63. 
Another miR-200 family member, miR-205, exhibits one of the highest levels of expression in 
skin stem cells. Significantly attenuated neonatal epidermal and follicular development occur 
as a consequence of miR-205 knockdown, resulting in thinner skin (26). Phosphorylated 
Protein Kinase B (pAKT), previously shown to be involved in skin stem cell renewal and 
proliferation (27), was reported to be downregulated in the knockout model, as miR-205 
directly targets and represses negative regulators of PI3K signalling.  Proliferation, therefore, 
of skin stem cells appears to occur via miR-205-mediated mechanisms which maintain pAKT.  
In addition to p63 expression, interfollicular, sebaceous gland, and hair follicle stem cells also 
express K5 and K14. Maintenance of miR-125b in cells expressing K14 was reported to sustain 
stemness, resulting in aberrant skin morphogenesis in the form of a thickened epidermis, lack 
of hair follicle development, and enlarged sebaceous glands, plausibly via an attenuation of 
Blimp1 protein level. The data suggest that this dysregulated follicular development is due to 
an increased number of early bulge cell divisions in the outer root sheath, restricting cell lineage 
commitment. Interestingly however, upon restoration of miR-125b to normal levels, these 
effects were reversed (28). MiR-125b does not, however, influence stem cell maintenance or 
activation, suggesting that the function of this miR is to primarily enhance stem cell renewal. 
Overall, these results indicate that miR-125b possesses the ability to repress stem cell 
differentiation, which appears logical given that miR-125b expression is low in early stem cell 
progeny.  
In terms of hair follicle morphogenesis, the Wnt/β-catenin pathway is an important regulator 
of hair follicle specification; during development, augmentation of β-catenin results in failed 
hair follicle differentiation (29), while similarly, Runx1 expression is also essential for 
follicular differentiation (30). Furthermore, Bone morphogenetic protein (BMP) ligands and 
antagonists are key, as evidenced by deletion of the BMP antagonist Noggin which attenuates 
development of the hair follicle (31). MiR-214 targets β-catenin; when overexpressed in 
keratinocytes, miR-214 inhibits proliferation and consequently hair follicle development due 
to attenuation of β-catenin and Lef-1. MiR-214, therefore, is a key regulator of Wnt signalling, 
which itself is key in follicular morphogenesis (32).   
Smad proteins, which are signal transducers of the TGF signalling pathway, are also involved 
in follicular development via mediation of BMP signalling and inhibition of Wnt/ β-catenin 
signalling (33). Interestingly, Smads also regulate miR expression through transcriptional and 
post-transcriptional mechanisms (34), further supporting the importance of the TGF- β 
superfamily and miRs in the skinBMPs are expressed in the epidermis and mesenchyme, and 
are involved in skin development and tissue remodelling (35); BMP4 treatment resulted in 
significant inhibition of miR-21 expression in primary mouse keratinocytes. Similarly, 
overexpression of the BMP antagonist Noggin significantly augments miR-21 in a transgenic 
mouse model (36). Furthermore, the BMP4-mediated inhibition of cell proliferation and 
migration was prevented by miR-21. Given that miR-21 is consistently overexpressed in a 
variety of tumour types, these findings suggest a mechanism by which the BMP pathway 
inhibits miR-21 in order to maintain normal function of the skin.  
Embryonic RUNX1 deletion in the epidermis causes delayed hair follicle regeneration due to 
failure of bulge stem cell proliferation (37). In contrast to epidermal development whereby 
elevated β-catenin leads to a reduction in hair follicle differentiation, during adulthood, high 
levels of β-catenin cause abnormal growth of hair follicles (29). The aforementioned BMP 
pathway mediates bulge stem cell quiescence in adult mice, and as BMP expression reduces, 
bulge stem cells activate and augment hair follicle regeneration (38).  
In terms of dermal homeostasis, miR-145 is highly expressed in dermal fibroblasts, however, 
expression was reported to be significantly downregulated during reprogramming to 
pluripotent stem cells. Inhibition of miR-145 resulted in an elevation in epithelial markers, and 
a reduction in mesenchymal markers, suggesting mesenchymal to epithelial transitioning, a key 
process in reprogramming of somatic cells to induced pluripotent stem cells. It seems clear, 
therefore, that the reduction in miR-145 significantly contributes to homeostatic control of the 
dermis via a switch from dermal fibroblasts to stem cells (39), which themselves can be 
programmed to a different cell type.  
The literature discussed thus far demonstrates that a large number of miRs exert significant 
regulatory effect on the fine tuning of a variety of signalling pathways involved in epidermal 
and dermal development and homeostasis.  
  
Table 1 – Summary of miRs involved in skin development and homeostasis. 
*iASPP = inhibitor of apoptosis stimulating protein of p53; BMP4 = bone morphogenic protein 4.  
miR  Cell/Model Role 
203. Foetal/adult skin 
(human) (22). 
Regulator of keratinocyte differentiation. 
34a/34c. Keratinocytes (mouse) 
(24). 
p63-regulated repression of -34a/34c controls 
cell cycle progression. 
574-3p/720. Neonatal keratinocytes 
(human) (25). 
Negatively regulated by iASPP*. Depletion of 
iASPP = miR expression and cell differentiation 
205. Mouse models (26). Neonatal epidermal and follicular development. 
125b. Mouse models (28). Enhances stem cell renewal and inhibits stem 
cell differentiation. 
214. Mouse 
models/keratinocytes 
(32).  
Inhibits follicular development via targeting β-
catenin. 
21. Mouse 
models/keratinocytes 
(36). 
Inhibits effects of BMP4* on cell 
proliferation/migration, leading to aberrant 
growth. 
145. Human dermal 
fibroblasts (39). 
Downregulated during reprogramming of 
somatic cells into pluripotent stem cells 
3.  MicroRNAs in Wound Healing and Skin Regeneration  
The underlying molecular mechanisms that mediate the development and homeostasis of the 
skin that have been discussed thus far all refer to processes that occur in healthy, undamaged 
skin. However, when injury occurs, differing signals, including miRs, coordinate the many 
stages of skin regeneration. The principal stage, haemostasis, is characterised by 
vasoconstriction which reduces blood flow, and platelet degranulation which activates fibrin, 
a protein involved in clotting. The second phase involves inflammation, whereby neutrophils 
immediately migrate to the wound and phagocytose pathogens and tissue debris. Monocyte-
derived macrophages cause efferocytosis which aids in the resolution of the acute inflammatory 
response. Proliferation then occurs, which is characterised by a number of processes which 
assist in the formation of new tissue; several cell types, in particular keratinocytes, fibroblasts, 
and endothelial cells, coordinate re-epithelialisation, collagen deposition, angiogenesis and 
granulation tissue formation. Finally, the remodelling phase involves full formation of the 
epidermal barrier primarily via extracellular matrix protein synthesis and apoptosis of immune 
cells. Scar formation may also occur during this phase, thought to be a consequence of aberrant 
inflammation, re-epithelialisation, and collagen deposition. 
 
3.1. Haemostasis 
MiR-143-145 appears to be essential during haemostasis, as evidenced by attenuated 
vasoconstriction,  a critical event during the early stages of wound healing, and impaired 
vascular smooth muscle cell (VSMC) differentiation in miR-143-145 knockout animals when 
compared with age-matched wildtype controls (40). Platelet-derive growth factor (PDGF) 
induces miR-15b, which is essential for VSMC proliferation (41). This mimics previous 
findings which showed that PDGF elicited miR-221 upregulation concomitantly with VSMC 
proliferation via  downregulation of c-Kit (42).  
Fibrinogen, the precursor to fibrin which causes clots at the site of skin injury, is regulated by 
miRs with attenuation of the FGB transcript occurring due to miR-409-3p overexpression. 
MiR-29 reduced the levels of all three fibrinogen transcripts, FGA, FGB, and FGG (43). 
Each of the aforementioned stages do not necessarily occur in isolation, as evidenced by miR 
regulation of overlapping haemostatic and inflammatory mechanisms. The pleiotropic cytokine 
IL-6 is a significant inducer of fibrinogen synthesis (44), which itself is regulated by the 
transcription factor STAT3. Expression of the miR-17.92 family transcripts, miR-18a, miR-
19a, and miR20a, were elevated after 24 hours of IL-6 treatment in both hepatoma cells and 
hepatocytes. Moreover, miR-18a was able to augment STAT3 transcriptional activity in HepG2 
cells, which, in addition to fibrinogen protein upregulation following miR-18a transfection of 
IL-6 stimulated cells, highlights that a positive feedback loop may exist by which miR-18a and 
the STAT3 pathway, and subsequent IL-6/fibrinogen activation, upregulate one another during 
the acute phase response (45).  
Although these data do not directly pertain to cells located in the skin, the underlying 
mechanisms may still be applicable however. 
Table 2 – Summary of miRs involved in haemostasis during skin regeneration. 
*VSMC = vascular smooth muscle cell 
 
3.2. Inflammation  
The inflammatory phase, as described above, depends on recruitment of immune cells to the 
site of the wound (46). Differentiation of blood monocytes into macrophages in the injured 
tissue is essential in order to mount an effective phagocytic response. This process involves a 
complex cascade of interlinked events in which miRs have been identified. For example, 
activation of the macrophage colony stimulating factor receptor (M-CSFR) gene due to miR-
424-mediated nuclear factor I type A (NFI-A) transcription factor downregulation has been 
reported (47). Additionally, computational analysis revealed that the transcription factors 
CEBPB, CREB1, ELK1, NFE2L2, RUNX1, and USF2, which are involved in monocytic 
differentiation, target miR-21, -424, -155, and -17-92 (48).  
Furthermore, albeit using fibroblast-like synoviocytes isolated from rheumatoid arthritis (RA) 
patients, Nakamuchi et al. (49) were able to demonstrate that miR-124a impaired monocyte 
chemoattractant protein 1 (MCP-1) expression which may have significant implications for 
monocyte migration following skin injury.  
Efferocytosis of apoptotic cells by these differentiated macrophages is critical, and has been 
shown to induce miR-21, while this miR also augmented efferocytosis, thereby demonstrating 
that a positive feedback loop exists. Of functional consequence, both post-efferocytotic and 
experimentally induced miR-21 were able to suppress LPS-induced NF-κB activation and TNF-
α expression. In addition, efferocytosis, and thus miR-21, augmented IL-10, which together 
indicates that miR-21 dampens pro-inflammatory mediators and enhances anti-inflammatory 
signalling (50).  
TLRs enable inflammatory cells to recognise microbial pathogens, thereby aiding in the 
regulation of the innate inflammatory response. LPS, which is recognised by TLR4, has been 
shown to augment miR-146a and -146b in primary monocytes isolated from cord and adult 
blood (51), in addition to the monocytic cell line THP-1, whereby these miRs were shown to 
downregulate IRAK1 and TRAF6, and thus, negatively regulate TLR signalling (52). LPS also 
upregulated miR-155. 
miR Cell/Model Role 
143-145. Mouse models (40). Essential for VSMC* differentiation, and 
functionally, vasoconstriction and vasodilation. 
15b. Pulmonary artery 
SMCs (41). 
Induced by platelet-derived growth factor, 
which inhibits SMC-specific gene expression 
and promotes cell proliferation. 
221. Pulmonary artery 
SMCs (42). 
Induced by platelet-derived growth factor, 
which inhibits SMC-specific gene expression 
and promotes cell proliferation via attenuation 
of c-kit. 
409-3p/29. HuH7 (liver) cell line 
(43). 
Attenuates Fibrinogen gene (FGA, FGB, FGG) 
expression. 
18a/19a/20a. HepG2 (liver) cell line 
(45).  
IL-6 stimulation augmented expression of all 
three miRs. MiR-18a increased STAT3 
activation and Fibrinogen protein level. 
Similarly, miR-147 was reported to be inducible by TLR stimulation, with binding of NF-κB 
and STAT1α to the miR-147 promoter also observed (53). MiR-147 knockdown resulted in 
increased TNF-α and IL-6 protein concentrations, demonstrating that this miR is a significant 
negative regulator of TLR-induced inflammatory responses in macrophages, thereby 
preventing aberrant inflammation which could be causative of scar formation.  
In addition to the aforementioned LPS-induced upregulation of miR-155 (52), the same group 
then reported that IFN-β also augmented miR-155 expression (54); the functional consequence 
of which was not identified, in contrast to the role of miR-146a. More recently however, 
Jablonski et al. (55) demonstrated that miR-155, which was upregulated in LPS and IFN-γ 
treated macrophages, suppresses a number of a genes, which drives the transformation to a 
classically activated ‘M1’ pro-inflammatory, anti-fibrotic macrophage phenotype in vitro. 
MiR-155 deficient mice exhibited accelerated wound closing concomitantly with increased 
numbers of macrophages at the wound site following punch biopsy (56). Consistent with 
Jablonski et al’s findings, treatment of these knockout mice with IL-4, the main cytokine 
involved in ‘M2’ or alternative macrophage phenotype activation, which is characterised by 
pro-fibrotic properties, induced the expression of the fibrotic protein FIZZ1. As expected, type-
1 collagen deposition was elevated in this system. Combined, these data show that miR-155 
inhibits M2 polarisation in favour of an inflammatory phenotype, and also that an overlap exists 
between the inflammatory phase and the growth of new tissue in the proliferation phase. MiR-
-155 is now also recognised as a multifunctional miR; elevated expression has been reported 
in activated B and T cells (57), synovial fibroblasts isolated from RA patients (58), and 
malignant tumours (59). Interestingly, it also regulates BMAL1, an intrinsic component of the 
circadian clock, that regulates circadian rhythm and oscillations (60). 
IL-10, through activation of, and also secretion by alternatively activated ‘M2’ macrophages, 
typically possess anti-inflammatory properties. MiR-4661 transfection of RAW 264.7 
macrophages resulted in augmented mRNA and protein levels of IL-10 (61). Recently, miR-
142 has also been found to be critical to appropriate wound healing through the regulation of 
neutrophil actin cytoskeleton gene modifiers as demonstrated by miR-142 KO mice that have 
abnormal wound closure rates (62).  
The literature discussed above all pertains to inflammatory regulation by monocytes and 
macrophages; however, miRs also appear to regulate inflammatory responses in keratinocytes 
and in inflammatory skin disorders. 
TLR2 stimulation of keratinocytes also upregulates the expression of miR-146a, via NF-κB 
and MAPK, with this overexpression attenuating neutrophil chemoattraction due to 
downregulated production of IL-8, TNF-α and CCL20, with the reverse occurring when miR-
146a was inhibited (63). MiR-146a is also significantly associated with the inflammatory skin 
conditions atopic dermatitis (AD) and psoriasis.  For example, miR-146a has been shown to be 
overexpressed in keratinocytes and skin lesions of AD patients (64), and functionally, appears 
to suppress NF-κB-dependent genes. Patients suffering from psoriasis exhibit miR-146a 
overexpression in skin lesions, which, as above, impairs neutrophil chemoattraction of 
keratinocytes. Genetic deficiency of miR-146a elicits an elevation in skin inflammation, in 
addition to earlier onset, due to epidermal hyperproliferation and augmented neutrophil 
infiltration (65). Upon administration of a miR-146a mimic, IL-17-driven inflammation was 
suppressed, and the inflammatory response magnified upon inhibition, clearly demonstrating 
that miR-146a possesses a key role in the regulation of skin inflammation.  
MiR-155 is also associated with chronic inflammatory skin disorders, including AD and 
vitiligo. Overexpression of miR-155 was found in both CD4+ T cells and AD patient skin 
samples. A positive correlation was also observed between expression of the miR and AD 
disease severity, Th17 cell percentage, IL-17 mRNA expression and plasma concentrations, 
which was further exacerbated upon transfection of a miR mimic, while an inhibitor elicited 
contrasting effects (66). Th17 cells have previously been postulated to significantly contribute 
to AD pathology, therefore it appears plausible that miR-155 contributes to disease progression 
due to augmentation of these cells (67). Furthermore, expression of miR-155 was reported to 
be elevated in the epidermis of vitiligo patients. When overexpression was induced in primary 
melanocytes and keratinocytes, genes associated with melanogenesis were downregulated (68). 
These data indicate that miR-155 is a key regulator in the pathogenesis of the chronic skin 
conditions such as AD and vitiligo. 
The reviews published by Rozalski et al. (68, 69) and Hawkes et al. (70) outline the extensive 
number of aberrations in miR expression associated with AD and psoriasis, respectively, and 
can be referred to for further discussion on these diseases outside the remit of this review.  
Altogether the literature presented in section 3.2 demonstrates that a vast number of miRs 
regulate both the induction and resolution of inflammation during this stage of skin 
regeneration.   
 
Table 3 – Summary of miRs involved in inflammatory phase of skin regeneration. 
 
miR Cell/Model Role 
424. NB4 cell line (47). Upregulation during monocyte/macrophage 
differentiation. Downregulates NFI-A 
transcription factor, activating M-CSFR*.  
21/424/155/17-92. THP-1 cell line (48). Targets of monocyte differentiation 
transcription factors.  
124a. Rheumatoid-arthritis 
fibroblast-like 
synoviocytes (49). 
Impairs MCP-1* expression. 
21. Monocyte-derived 
macrophages (human) 
(50). 
Induces and is induced by efferocytosis. 
Suppresses LPS-induced NF-κB activation and 
TNF-α expression, and augments IL-10. 
146a/146b.  
 
 
 
 
Primary monocytes 
(cord and adult blood) 
(51). 
 
THP-1 cell line (52). 
Increased expression upon LPS stimulation.  
 
 
 
Downregulation of IRAK1 and TRAF6, and thus, 
TLR signalling.  
146a. 
 
 
 
 
 
Keratinocytes (human) 
(63). 
 
AD skin 
lesions/keratinocytes 
(64).  
 
Psoriasis skin lesions 
(65). 
 
KO mouse model (65). 
Upregulation following TLR2 stimulation and 
attenuated neutrophil chemoattraction. 
 
MiR-146a overexpression. 
 
 
 
Overexpression in skin lesions, impairing 
neutrophil chemoattraction. 
 
Earlier disease onset, increased skin 
inflammation, epidermal hypoproliferation, 
augmented neutrophil infiltration. IL-17-driven 
inflammation suppressed upon administration of 
miR-146a mimic.  
147. Peritoneal/alveolar 
macrophages (mouse) 
(53). 
 
RAW 264.7 cell line 
(53).  
 
Expression induced by TLR (LPS) stimulation. 
MiR-147 knockdown augmented IL-6 and TNF-
α concentrations. 
 
NF-κB and STAT1α bound to miR-147 
promoter. 
155.  
 
 
 
 
 
 
 
THP-1 cell line (52). 
 
Primary macrophages 
(mouse) (54). 
 
Primary macrophages 
(mouse) (55). 
 
 
KO mouse model (56). 
 
 
LPS-induced overexpression. 
 
IFN-β-induced overexpression. 
 
 
Upregulated in LPS/IFN-γ treated macrophages. 
Drives transformation to pro-inflammatory ‘M1’ 
phenotype. 
 
Augmented wound closing correlated with 
increase number of infiltrating macrophages. IL-
4 (‘M2) treatment increased FIZZ-1 expression 
and type 1 collagen deposition. 
*M-CSFR = macrophage colony stimulating factor receptor; MCP-1 = macrophage chemoattractant 
protein-1 
 
3.3. Proliferation and Remodelling 
The transition between inflammatory and proliferative phases is an essential aspect of wound 
healing and regeneration, and may be regulated by miR-132, which is induced by TGF-β1 and 
TGF-β2 in keratinocytes. MiR-132 was shown to augment keratinocyte proliferation, and 
similarly to miR-146a and miR-155, attenuate their chemoattractive ability via NF-κB 
suppression (71). It is likely, therefore, that miR-132 serves to mediate inflammation during 
progression to the proliferative phase, which is likely considering that miR-132 also suppresses 
NF-κB signalling. 
Mobilisation of hair follicle and interfollicular epidermal stem cells during the inflammatory 
stage, and migration and proliferation of keratinocytes, cause skin re-epithelialisation. In an 
acute human skin wound model, miR-21 and miR-130a have been reported to delay re-
epithelialisation (72). Conversely however, TGF-β1-induced miR-21 expression was able to 
augment keratinocyte migration in HaCaT cells (73). Consistently, knockdown of miR-21 
decreased TGF-β1-induced keratinocyte migration. Following mouse skin punch biopsies, 
miR-21 expression was elevated, while miR-21 knockdown impaired re-epithelialisation. Both 
in vitro and in vivo data from this study strongly suggest that miR-21 drives keratinocyte 
migration and proliferation. The data regarding miR-21 appear somewhat conflicting, however, 
these differences may be due to the use of human cell lines and mouse skin model in one 
investigation (73), and the use of an acute human skin wound model in the other (72). 
Nonetheless, it is clear that miR-21 possesses a significant regulatory role in keratinocyte 
migration and thus, re-epithelialisation.  
In addition to the results reported by Yang et al. (73), Li et al. (74) showed that another 
transforming growth factor, TGF-β2, known to be highly expressed in skin wounds, elicits a 
significant elevation in the expression of miR-31 and subsequent proliferation in primary 
human keratinocytes, with miR-31 knockdown causing contrasting effects. Interestingly, EMP-
1 appeared to mediate the effects of miR-31; a significant negative association was observed 
between the two, while silencing of EMP-1 exerted similar effects as miR-31 overexpression 
in terms of migratory capacity. In vivo, punch biopsy of a human wound healing model 
155. 
 
CD4+ T cells/AD skin 
lesions (66). 
 
 
 
Vitiligo patient 
epidermis/melanocytes 
and keratinocytes (68). 
Overexpression of miR-155. Expression 
correlated with disease severity, Th17 cell 
percentage, IL-17 mRNA and plasma 
concentrations. 
 
Overexpression of miR-155 in epidermis. 
Induced overexpression in vitro inhibited genes 
associated with melanogenesis. 
4661. RAW 264.7 cell line 
(61). 
 
Elevated IL-10 mRNA and protein following 
miR transfection. 
142. KO mouse 
model/wound-
infiltrated neutrophils 
(mouse) (62). 
Impaired wound closure rate. Altered neutrophil 
phagocytosis. Actin cytoskeleton regulators Rho 
and Rac elevated, suggesting involvement in 
neutrophil migratory capacity. 
demonstrated that miR-31 gradually increased from the first day, and thus, the inflammatory 
phase, until day seven during the proliferative phase (74). This not only supports the postulation 
that considerable overlap exists between the phases of skin regeneration, but also that miR-31 
regulates re-epithelialisation in a similar manner to miR-21. 
An inverse correlation between RAN and RAPH1, and miR-203 expression was observed (75). 
These two proteins, involved in cell proliferation and survival, and cytoskeleton remodelling 
respectively, have shown to be direct targets of miR-203. Furthermore, both silencing of these 
targets and overexpression of miR-203 in vitro using human neonatal epidermal keratinocytes 
resulted in attenuated cell proliferation and migratory capacity. In vivo, elevated miR-203 
expression was reported in the suprabasal epidermal layers surrounding the wound in a mouse 
skin model, however, minimal expression was found in the migrating keratinocytes themselves. 
MiR-203, could, therefore, be a possible target for therapeutic intervention, given the need for 
keratinocyte migration and proliferation in re-epithelialisation, and the evident role miR-203 
possesses in terms of inhibiting these key processes.  
Reactive oxygen species released by phagocytic cells during the inflammatory phase appear to 
drive angiogenesis as evidenced by H2O2-induced VEGF augmentation in keratinocytes (76), 
in addition to impairment of angiogenesis upon antioxidant treatment in human microvascular 
endothelial cells (77). In the study conducted by Shilo and colleagues (77), despite elevated 
VEGF expression following Dicer knockdown, the angiogenic response of these endothelial 
cells was compromised, demonstrated by attenuated tube formation and cell migration. 
Furthermore, Dicer knockdown in human endothelial cells elicited aberrant expression of a 
number of angiogenic genes concomitantly with attenuated cell proliferation (78). Similarly, 
mice that lacked the first two exons of the Dicer gene exhibited under-developed blood vessels 
(79). 
Moreover, miR-221 and -222 transfection of endothelial cells results in a reduction in c-Kit 
protein levels through targeting the c-Kit 3’UTR (80). c-Kit signalling involves Akt and Erk1/2 
pathways, similarly to VEGF (81), while activation of c-Kit has been shown to also upregulate 
VEGF (82). Thus, miR-221 and -222 appear to regulate angiogenesis directly through c-Kit, 
which itself is the receptor for stem cell factor, and indirectly via c-Kit-dependent modulation 
of VEGF. Tissue hypoxia due to reduced blood supply of the damaged skin is also known to 
be an inducer of angiogenesis during regeneration; ETS-1, the angiogenesis-related 
transcription factor, in addition to MMP1 and VEGFR1, are negatively regulated by miR-200b. 
Expression of ETS-1 was de-repressed following hypoxia-induced downregulation of miR-
200b, which augmented angiogenic capacity (83), again, in experiments that utilised 
endothelial cells.  
Seven days post-skin excision injury in mice, over 50 miRs exhibited altered expression of 
greater than two-fold, 33 of which were upregulated and 21 downregulated. The former 
included miR-21, -31, and -203, and the latter, miR-249. Prior to skin injury, miR-21 expression 
was undetectable in the epidermis, however, following excision, expression in the migrating 
epithelial cells was augmented greatly (84). Furthermore, mesenchymal expression of miR-21 
was also elevated in granulation tissue.  Overexpression of miR-21 has been shown to inhibit 
granulation tissue formation in a rat wound model (72), which could have significant 
implications for therapeutic targeting in chronic non-healing wounds. Interestingly, TGF-β 
signalling has been robustly shown to not only induce miR-21 expression in keratinocytes (85), 
but is also a key pathway involved in the contraction of wounds (86).  
In terms of collagen deposition, augmented miR-29a expression was shown to occur 
concurrently with a reduction in collagen type 1 alpha 2 (COL1α2) and VEGF-A following 
thermal skin injury (87). As miR-29a began to decrease, COL1α2 and VEGF-A began to 
increase, suggesting that they were targets of miR-29a, which was discovered to be the case. 
This was further demonstrated by inhibition of miR-29a, which elicited a significant elevation 
in fibroblast proliferation and migration. The naturally occurring downregulation of miR-29a 
during skin regeneration, therefore, appears to be a mechanism by which type 1 collagen 
synthesis and angiogenesis are enhanced, aiding the regenerative process. In a similar manner, 
Zhu et al. (88) corroborated these findings by recently reporting that miR-29a exhibited 
downregulation in a murine thermal wound model, however, much more drastic attenuation of 
miR-29b was observed in both thermal and excisional wound models, concomitantly with a 
significant elevation in heat shock protein 47 (HSP47) expression and a gradual increase in 
COL1α1. Of note was that TGF-β1 inhibited miR-29b transcription in skin fibroblasts; given 
that miR-29b overexpression impairs biosynthesis of COL1α1, this further highlights the 
important of TGF-β signalling in collagen deposition.   Together, these data demonstrate that 
the miR-29 family possesses essential regulatory roles in mediating fibrotic processes and 
collagen deposition associated with wound contraction and scar formation. It has long been 
suggested that miR-29 is “fibromiR” and is a critical target in fibrotic diseases where 
constitution of miR-29 is currently being investigated; the miR-29 family shares seed 
sequences complementary to conserved binding sites of multiple collagen genes (89) and 
downregulation of miR-29a in SSc, a major fibrotic disease, has also been shown (90); 
experimentally, this study reported that overexpression of miR-29a caused a decrease in type I 
and type III collagen mRNA, with the opposite effects observed upon miR-29a knockdown. 
These data were corroborated, as increased miR-29a expression reversed the fibrotic SSc 
fibroblast phenotype due to attenuation of collagen and TIMP-1, which itself is regulated by 
the miR-29a target TAB1 (91).  
 
MiR-145 appears to regulate a similar cascade; in vivo, miR-145 levels and α-smooth muscle 
actin (α-SMA) were significantly augmented in hypertrophic skin tissue compared with 
controls, while TGF-β1-induced elevation of miR-145 attenuated expression of KLF4, thereby 
de-repressing α-SMA in skin myofibroblasts (92). Thus, aberrant miR-145 appears to contribute 
to scarring due to α-SMA’s contribution to permanent tissue contracture. Furthermore, 
inhibition of miR-145 attenuated not only COL1α1 expression, but also TGF-β1 secretion, and 
migration. 
A reduction in miR-129-5p also appears to possess a significant regulatory role in aberrant 
fibrotic processes associated with SSc pathology; in vitro, IL-17RA siRNA transfection 
significantly reduced expression of the antifibrotic miR-129-5p. Moreover, TGF-β1-induced 
downregulation of IL-17A signalling due to attenuation of the receptor IL-17RA expression in 
SSc fibroblasts releases the inhibitory effect of miR-129-5p on type 1 collagen, thereby 
promoting fibrosis (93).  
 Figure 3 – Schematic representing miRs involved in collagen regulation and scleroderma 
pathogenesis. MMP-1 = matrix metalloproteinase-1; ITGB3 = integrin beta 3; Col. = collagen. 
References: (88, 90, 91, 93-99). 
  
Table 4 – Summary of miRs involved in proliferation and remodelling phase of skin 
regeneration. 
 
A paucity of literature appears to exist concerning miR-mediated longer term remodelling of 
the skin, whereby type III collagen is replaced by type I collagen and re-aligned. This area, 
therefore, warrants further investigation so that the molecular mechanisms that govern wound 
healing are fully characterised.  
miR Cell/Model Role 
132. Keratinocytes (human) 
(71). 
Augments proliferation and attenuate 
chemoattractive ability. 
21. 
 
 
 
 
 
 
 
 
Skin punch biopsy 
(human/rat) (72). 
 
HaCaT cell line (73). 
 
 
Excisional wound 
model (mouse) (84). 
 
HaCaT cell line (85). 
 
Inhibits re-epithelisation.  
 
 
TGF-β1-induced miR-21 expression increased 
keratinocyte migration. 
 
Elevated expression in migrating epithelial cells 
following skin injury. 
 
TGF-β signalling induced miR-21 expression. 
MiR-21 blocks inhibition of growth by TGF-β1. 
130a. Healthy skin punch 
biopsy (human) (72). 
Inhibits re-epithelisation.  
 
31. Keratinocytes (human) 
(74). 
 
Skin punch biopsy 
(human) (74). 
Expression induced by TGF-β2 
 
 
Expression gradually increased from day 1 until 
day 7.  
203. HEKn cells (75).  
 
 
Skin punch biopsy 
(mouse) (75).  
Overexpression attenuated cell proliferation and 
migratory capacity.  
 
Expression found in suprabasal epidermal 
layers. Minimal expression in migrating 
keratinocytes. 
221/222. Endothelial cells 
(human vascular) (80).  
Transfection reduces c-Kit, thereby reducing 
angiogenesis. 
200b. Dermal microvascular 
endothelial cells 
(human) (83).  
De-repression of angiogenic transcription factor 
ETS-1, and thus increased angiogenesis, 
following hypoxia-induced miR-200b 
downregulation. 
29a. 
 
 
 
 
Thermal wound injury 
model (rat)/BJ 
fibroblast cell line 
(human) (87). 
 
Excisional and thermal 
wound models 
(mouse) (88). 
 
NRK-52E cell line 
(89).  
 
SSc fibroblasts/skin 
sections (human) (90). 
 
 
 
 
Dermal fibroblasts 
(human) (91).  
Augmented expression concurrently with 
attenuated COL1α2 and VEGF-A (confirmed as 
targets of miR-29a in vitro).  
 
 
Expression unaltered in excisional wound 
model, but downregulated in thermal wound 
model. 
 
3’-UTR of numerous collagen genes targeted by 
miR-29 family. 
 
Downregulation in SSc fibroblasts and skin 
sections. Overexpression of miR-29a caused a 
decrease in type I and type III collagen mRNA, 
with the opposite effects observed upon miR-
29a knockdown. 
 
Transfection of miR-29a decreased collagen and 
TIMP-1. TAB-1, a regulator of TIMP-1, found 
to be a novel target of miR-29a.  
 3.4. Foetal Wound Healing 
Although not as common as tissue injuries in adults, foetal skin possesses the capacity to heal 
without scarring due to its own unique molecular response to injury. Microarray analysis has 
revealed a plethora of differentially expressed genes between mid-gestational and post-natal 
dermal wounds, concomitantly with the expected full re-epithelialisation and lack of scarring 
in the former, and dense scar tissue present in the latter mice (100). Most importantly, a number 
of these differentially regulated genes were involved in growth factor signalling and cell 
proliferation. Further support for the significance of growth factors in the striking phenotypic 
differences between early-mid foetal skin and late foetal or post-natal skin has been reported. 
Unwounded human adult and foetal skin possess distinct TGF-β expression profiles, with lower 
expression of all three isoforms found in foetal skin, in addition to differential ratios compared 
with adult skin (101). Given the role of TGF-β in the regulation of extracellular matrix 
deposition, it was unsurprising that deletion of TBF-βRII significantly attenuated dermal scar 
formation and enhanced epidermal proliferation in post-natal fibroblasts (102). The dermis of 
TBF-βRII knockout mice also exhibited a decrease in collagen deposition together with 
augmented keratinocyte proliferation, and thus, re-epithelialisation (86).  
In addition to growth factors, aberrant collagen composition and organisation also contribute 
to the scarring phenotype which is not characteristic of non-scarring foetal skin. Mid-
gestational rats exhibited a much higher collagen type III:collagen type I ratio than adult rats 
following surgical dermal injury (103). In corroboration, Goldberg et al. (104) discovered that 
COL1α1 expression was attenuated following injury during mid-gestation only, while COL1α2  
COL1α3 were significantly lower in the late-gestational group, in both wounded and normal 
conditions. The pattern of collagen deposition in the mid-gestational mice was characteristic 
of the surrounding unwounded skin with no visual evidence of scarring, whereas irregular 
collagen deposition in the late-gestational mice was observed, suggesting scar tissue formation. 
In vivo, undamaged human foetal skin also exhibited a greater type III:type I ratio than 
adolescent, adult, and elderly skin (105).  
A comparison of mid-gestational (non-scarring phenotype) and late-gestational (scarring 
phenotype) mouse skin revealed a number of differentially expressed miRs and predicted 
targets between the two time-periods and associated phenotypes. In particular, expression of 
miR-29b, -29c, and 338-3p was altered 24, 20, and 19-fold, respectively (106). Importantly, 
29b. Excisional and thermal 
wound models 
(mouse) (88). 
 
Downregulation in both models. Transcription 
inhibited by TGF-β1, enhancing collagen 1 
production.  
145. Hypertrophic scar 
tissue (human) (92). 
 
Dermal fibroblasts 
(human) (92).  
α-SMA and miR-145 elevated. 
 
 
Expression augmented by TGF-β1, causing a 
decreasing in KLF4, thereby de-repressing α-
SMA. 
129-5p. SSc patient skin and 
serum samples (93). 
IL-17A transfection attenuated miR-129-5p 
expression. Downregulation of IL-17A 
signalling by TGF-β1 releases inhibitory effect 
of miR-129-5p on collagen type 1.  
bioinformatic analysis revealed that the differentially expressed miRs were also shown to 
putatively target a number of signalling pathways, including TGF-β. Thus, it could be 
postulated that miRs may be significant regulators of the foetal non-scarring phenotype due to 
modulation of TGF-β signalling. The role of the miR-29 family in the regulation of collagen 
expression has already been discussed within this review, and may present a further molecular 
mechanism by which differential miR expression contributes to scarless healing.  
 
  
4. MicroRNA Therapeutics 
In addition to the essential role of miRs in normal development of the skin and regeneration 
from injury, they also play a pivotal role in the pathogenesis of a vast number of diseases, 
including conditions of the skin such as vitiligo, psoriasis, SSc, dermatomyositis, and 
melanomas. The detection of miRs in serum or plasma, which resist degradation due to 
containment within extracellular vesicles, are emerging as non-invasive diagnostic markers for 
major diseases like cancer (107) and cardiovascular disease (108), in addition to rheumatoid 
arthritis (109), SSc (110), and as a biomarker of the severity of inflammation in children with 
AD (111). 
In terms of treatment of specific conditions, recent research has demonstrated that miRs can 
manipulated via administration of miR mimics which are chemically synthesized, double-
stranded RNAs that mimic endogenous miRNAs, while antagomiRs are chemically engineered 
oligonucleotides that inhibit miRNAs. There is potential for both to be used therapeutically for 
tissue regeneration or fibrotic diseases. As highlighted by Christopher et al. (112), however, a 
number of steps are required before an miR could potentially be used as an effective therapy, 
namely; profiling of the miR associated with a specific disease state, in vitro studies to validate 
the miR using loss/gain of function, in vivo studies to investigate pharmacokinetics, followed 
by clinical trials if all other stages are successful. Other important considerations are specificity 
of binding to the target miR, resistance to degradation, and the method of in vivo delivery.  
Chemical modification of the miRs are required to enhanced stability and stop the breakdown 
by copious endogenous nucleases, in addition to improving affinity of the antagomiR to the 
cognate miR. Such examples are Locked Nucleic Acids (LNAs), whereby the ribose of the 
RNA nucleotide is chemically modified by the addition of a 2’-O, 4’-C-methylene bridge (113). 
Alternatively, tiny LNAs which are 8-mer LNA anti-miRs that specifically target the miR seed 
region, can be used (114). Chemical substitution of the 2’ hydroxyl group, to 2’O-methyl or 
2’O-methoxyethyl, for example, also occur (115).  
The issue of specificity is being addressed via a number of methods; sponge miRs, for example, 
contain several complementary binding sites to the specific miR of interest, whereas miR 
erasers utilise two copies of the exact miR complementary antisense sequence (116). Long non 
coding RNAs (lncRNA) are longer forms of RNA arbitrarily defined as 200nts and over, and 
often act as sponges to sequester faulty miR expression. Indeed, the X-linked lncRNA H19 is 
aberrantly expressed in keloids (117). Targeting of the miR to the correct tissue could also be 
employed by conjugating the chemically synthesised miR to a monoclonal antibody that 
identifies that specific tissue antigen, thereby ‘hitting the target’ and causing the miR to bind 
to its cognate mRNA. This could also be PEGylated to increase stability.   
Viral vectors have been utilised in order to deliver miR mimics or inhibitors. For example, 
adeno-associated virus (AAV) is a popular gene delivery system; however, a consistent issue 
which has inhibited the progression of some AAV therapies to human clinical trials is the 
induction of low grade immune activation (118). Lenti-viral vectors for delivery suffer from 
the same immunogenicity issues. MiR mimics for the tumour suppressors miR-34a and let-7 
have been successfully delivered in a complex with neutral lipid emulsion in mice (119). 
A number of miR therapies are currently in preclinical trials, with a small number having 
already met the requirements to advance to clinical studies. Although no miR therapies 
designed specifically for skin disorders are at this stage to the authors’ knowledge, MiRagen 
Therapeutics currently have an ongoing phase 1 clinical trial for MRG-201, a miR-29b mimic 
which is designed to attenuate collagen expression, as this is a true target of miR-29. A number 
of studies have also utilised miR mimics and antagomiRs in vitro, and could potentially inform 
future studies which may progress to clinical trials. 
Loss/gain of function studies are essential in order to validate particular miRs that may be 
future therapeutic targets with regard to skin disorders and/or healing. MiR mimics and 
inhibitors have shown that miR-200b expression was up- and down-regulated, respectively, in 
human microvascular endothelial cells, with a subsequent attenuation in tube formation and 
wound closure following mimic administration, with contrasting effects observed following 
addition of the 200b inhibitor (83). In a similar investigation, the addition of a miR-29b mimic 
to primary human dermal fibroblasts elicited a significant augmentation of miR-29b expression 
with a concomitant attenuation of HSP47 and COL1α1 expression. As expected, contrasting 
outcomes were observed following administration of an inhibitor (88). These miRs could, 
therefore, be future targets for therapeutic intervention. Furthermore, due to the data presented 
above by Gras and colleagues (92), they concluded that miR-145 may also be a promising 
target for future therapeutic intervention.  
With specific regard to the utilisation of antagomiRs, Krützfeldt et al. (120) have demonstrated 
that intravenous injection of antagomiRs against miR-16, -122, -192, and -194, resulted in a 
subsequent attenuation of the miR levels in a number of major tissues, including the skin. 
Subcutaneous injection of a miR-203 antagomiR attenuated miR-203 expression, but 
importantly, resulted in a greater number of proliferative cells in the dorsal epidermis of 
neonatal mice (23). Similarly, in a mouse excisional wound model, injection of an antagomiR 
to miR-155 attenuated expression as expected, in addition to phagocytic cell migration, pro-
inflammatory cytokine secretion, and COL1α1, COL2α1, and α-SMA expression. Functionally, 
this elicited an overall positive effect as demonstrated by better aligned and thinner collagen 
fibres upon wound healing (121). Most recently, topical epicutaneous administration of the 
miR-155 antagomiR elicited a reduction in collagen deposition and dermal thickening in 
bleomycin-induced fibrotic mice (122). Of greatest interest, however, was that due to the 
topical delivery method, miR-155 was downregulated only in the skin, and not liver, bone 
marrow, or blood cells.  
Direct injection of a miR-21 antagomiR to the dermis surrounding a would site did indeed 
attenuate expression of miR-21, however impaired collagen deposition and delayed wound 
healing were observed which the authors did not expect, and therefore, miR-21 may not be an 
effective therapeutic target for wound healing (84). 
Another issue is that targeting one specific miR might not be sufficient to elicit a significant 
clinical effect due to large redundancy among miRs; a reduction in one miR may have 
negligible effects on the protein output due to one or more miRs compensating for this. Thus, 
it may take multi-miR targeting approaches to repress a specific pathway.  
Whilst hematopoietic stem cell transplantation (HSCT) isn't an miR-based therapy per se, we 
hypothesize that miRs could be reset to non-aberrant levels thereby attenuating IL-6, TNF-R, 
and CD3+ cell numbers, which was indeed observed in the dermis of the patient presented in 
figure 4 (123). Concomitantly, restoration of the skin structure also occurred, which would be 
expected given the role of IL-6 in promoting fibrosis (124). It must be noted that no current 
data exists to support or refute this postulation however. 
  
Figure 4 – Hematoxylin and eosin (H.E.) and T cell (CD3) immunohistochemistry staining of 
a SSc patient’s dermis, before and after HSCT.  
5. Concluding Remarks and Future Directions 
Although originally referred to as ‘junk DNA’ with little to no biological function, it has 
become increasingly apparent that non-protein coding regions of the genome can still exert a 
multitude of diverse effects and are no longer deemed insignificant. Non-coding RNA are one 
such example that mediate a vast number of functions via post-transcriptional gene regulation, 
in the case of miRs (125).  
The skin and the underlying molecular mechanisms by which it develops, is maintained, and 
regenerated, while complex, has been reasonably well characterised at this point. Of interest 
however, is how these mechanisms can be manipulated in order to elicit salubrious outcomes 
in the context of wound healing or skin disorders such as scleroderma. Persistent perpetuation 
of dysregulated miRs in skin disorders suggest they are key players in disease progression, and 
may also, therefore, be promising biomarkers and/or therapeutic targets. Data thus far has 
highlighted a variety of potential therapeutic targets in vitro and using murine models, however, 
as discussed, a large number of stages and considerations are required prior to a specific miR 
becoming eligible for clinical trial. Further research should continue to identify and validate 
miRs associated with aberrant epidermal development and homeostasis associated with disease 
in the hope that efficient miR-based therapies may be established.  It may be possible in the 
future with the advent of viral gene delivery to alter the expression of miRs with the use of 
viral vectors providing immune activation is avoided. In particular SSc may be a tractable target 
for miR viral gene delivery due to the wealth of knowledge of miRs in this condition. 
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